Biotin-PFP ester | Chiral Building Blocks

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 120550-35-8 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Citations

Primary Amine-Functionalized Ligand Substitution and Biotinylation of Co (III) for Ligand-Anchored Artificial Metalloenzymes

Adams, Milo A ; Kincade, Jack A ; Runyan, Elle C ; Torraco, Ashley N ;

Abstract: Group IX metals in the+ 3-oxidation state can be incorporated into [Cp* MCl2] 2 complexes for the design and synthesis of new artificial metalloenzymes for biological functions. While previous studies have applied the more costly and less abundant rhodium-or iridium-(III) metals, use of a cobalt (III) metal center provides a low-cost route to preparing artificial metalloenzymes. Herein, a new metal cofactor is acquired through synthesis of a primary amine-functionalized Cp* ligand and subsequent complexation with a Co (III) metal center. Key signals corresponding to the Cp* and NH2 groups are visible by Fourier Transform Infrared spectroscopy where the aromatic signal of the Cp* and the stretching mode of the primary amine are present in their characteristic regions, supporting the formation of a tentatively assigned bis [dichloro-ⴄ5 (1-ethylamine-2, 3, 4, 5-tetramethylcylopentadienyl)-cobalt (III)]. Biotinylation of this complex would allow for pairing with engineered proteins to foster catalytic C—H activation, improving enzymatic processes in biological and biochemical applications.

Purchased from AmBeed: 120550-35-8

Product Details of [ 120550-35-8 ]

CAS No. :	120550-35-8
Formula :	C₁₆H₁₅F₅N₂O₃S
M.W :	410.36
SMILES Code :	[H][C@]12CS[C@@H](CCCCC(=O)OC3=C(F)C(F)=C(F)C(F)=C3F)[C@@]1([H])NC(=O)N2
MDL No. :	MFCD09952636
InChI Key :	DKTMDBQDSYQUEV-LEJLMFORSA-N
Pubchem ID :	11122445

Safety of [ 120550-35-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 120550-35-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	27
Num. arom. heavy atoms	6
Fraction Csp3	0.5
Num. rotatable bonds	7
Num. H-bond acceptors	8.0
Num. H-bond donors	2.0
Molar Refractivity	93.57
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	92.73 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.56
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.72
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	4.35
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	4.28
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	4.48
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.68

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.8
Solubility	0.065 mg/ml ; 0.000158 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-4.32
Solubility	0.0196 mg/ml ; 0.0000477 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-5.81
Solubility	0.000639 mg/ml ; 0.00000156 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	Yes
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.87 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	1.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	4.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	3.83

Application In Synthesis of [ 120550-35-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 120550-35-8 ]

[ 120550-35-8 ] Synthesis Path-Downstream 1~36

1
[ 120550-35-8 ]
[ 79750-47-3 ]
(S)-3-(4-Benzyloxycarbonylamino-phenyl)-2-[5-((3aR,6S,6aS)-2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-propionic acid methyl ester [ No CAS ]

References: [1]Tetrahedron Letters,1989,vol. 30,p. 1401 - 1404.

2
[ 14533-84-7 ]
[ 58-85-5 ]
[ 120550-35-8 ]

Yield	Reaction Conditions	Operation in experiment
96%	With triethylamine; In N,N-dimethyl-formamide; at 0 - 70℃; for 1h;	D-Biotin (1.00 g, 4.09 mmol) was dissolved in 20 mL DMF at 70 C and allowed to cool to rt. TEA (0.83g, 1.14 mL, 8.19 mmol) was added, followed by pentafluorophenyl trifluoroacetate (1.60 g, 0.98 mL, 5.73 mmol). The reaction was allowed to stir for 1 h at 0 C and became pink. Solvent was reduced to 1 mL in vacuo and the crude material was triturated with cold diethyl ether. The pFp ester product was recovered as a white solid (1.54 g, 96%). Biotin-pFp ester (1.00 g, 2.44 mmol) was dissolved in 10 mL DMF and cooled to 0 C. A flask containing a suspension of NaBH4 (3.4 mmol) in dry DMF (5 mL) was also cooled to 0 C. The pFp-ester was transferred dropwise via a cannula over 15 min and the mixture was stirred at 0 C. The reaction was followed by TLC and upon completion the cold mixture was acidified with 1 N HC1 and reduced to 1 mL in vacuo. The residue was triturated with cold diethyl ether and the product alcohol was recovered as a white solid (0.528 g, 94%). The alcohol (0.528 g, 2.29 mmol) and TEA (0.39 ml, 1.2 eq) were dissolved in DMF (10 mL) and added dropwise to a stirred solution of 4-nitrophenyl chloroformate (4-NCF, 1.38 g, 6.87 mmol, 3.0 eq) in DMF (10 mL) over a period of 1 h at -10C. The reaction mixture was allowed to warm to rt, stirred overnight, and subsequently and reduced to 1 mL in vacuo. The residue was triturated with cold diethyl ether. The nitrophenol carbonate product was recovered as a white solid (0.96 g, 95%). Fmoc-L-Lys-OH (1.03 g, 2.83 mmol, 1.3 eq.) was suspended under argon in anhydrous DMF (10 ml) containing DiPEA (0.50 ml, 1.3 eq.). To this white suspension, a clear solution of the nitrophenol-carbonate (2.18 mmol, 1.0 eq.) in anhydrous DMF (10 mL) was added drop wise under argon at rt over a period of 2 h. The reaction mixture was stirred for additional 4 h at rt, before the solution as acidified to pH 2 with 1 N HC1. All volatiles were evaporated under reduced pressure and the residue was triturated with cold diethyl ether. The crude product was purified by column chromatography (DCM : MeOH 95 : 5 v/v) to give the Fmoc-protected ncAA as a white solid. The Fmoc- protected ncAA was dissolved in 20% piperidine in DMF (5 ml) and stirred for 1 h at r.t.. All volatiles were removed under reduced pressure and the residue was triturated with cold diethyl ether. Drying of the residue in vaccuum yield the pure ncAA as a white powder (0.622 g, 71 %). 1H-NMR (D6-DMSO, 400 MHz): delta = 1.30-1.45 (m, 6H), 1.50-1.65 (m, 4H), 1.85 (m, 2H), 2.65 (d, J = 12.2 Hz, 1H), 2.84 (dd, J= 5.0 Hz, J= 12.2 Hz, 1H), 2.95 (m, 2H), 3.13 (m, 1H), 3.42 (m, 1H), 3.66 (m, 1H), 3.85 (dd, J= 13.8 Hz, J = 1.0 Hz 1H), 3.93 (t, J= 7.5 Hz, 2H), 4.17 (dd, J= 8.2 Hz, J= 7.3 Hz, 1H), 4.35 (dd, J= 8.1 Hz, J= 7.2 Hz, 1H), 7.11 (t, J= 5.4 Hz, 1H), 8.50 (br, 3H), 8.53 (br, 1H), 8.68 (br, 1H).13C-NMR (D6-DMSO, 100 MHz): 13C-NMR (CDCI3, 100 MHz): delta = 171.44, 163.29, 156.82, 64.00, 61.61, 60.35, 59.79, 55.95, 52.28, 39.10, 30.05, 29.35, 29.02, 28.78, 28,73, 25.91, 22.05. HR-MS (C17H31N4O5S): calculated: 403.20097, found: 403.20159.
81%		Biotin (5 g; 23.1 mmol; 1.0 eq) is suspended in anhydrous DMF (50 ml) and pyridine (2.07 ml; 25.4 mmol; 1.1 eq). After stirring for 5 minutes, pentafluorophenyl trifluoroacetate (PFP-TFA: 4.621 ml, i.e. 7.50 g; 25.4 mmol; 1.1 eq) is added. After stirring for one night, the reaction is finished, and the solvents are evaporated on the rotary evaporator. The evaporation residue is taken up in 100 ml of ethyl ether to suspend it, then filtered off on a fritted filter, and the cake is rinsed with a minimum of ether. Note: in the TLC a small trace of biotin is observed, but that will have no impact on what follows. m=7.106 g. Yield: 81%. TLC eluent: DCM/MeOH: 90/10.

References: [1]Patent: WO2018/207077,2018,A1 .Location in patent: Paragraph 0082.
[2]Organic Letters,2013,vol. 15,p. 1406 - 1409.
[3]Patent: US9266902,2016,B2 .Location in patent: Page/Page column 21.
[4]Chemistry of Natural Compounds,1989,vol. 25,p. 350 - 353.
Khimiya Prirodnykh Soedinenii,1989,p. 404 - 408.
[5]Journal of Medicinal Chemistry,2019,vol. 62,p. 5522 - 5540.
[6]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 625 - 637.
[7]Journal of the American Chemical Society,2009,vol. 131,p. 12091 - 12093.

3
[ 59483-84-0 ]
[ 58-85-5 ]
[ 120550-35-8 ]

References: [1]Chemistry of Natural Compounds,1989,vol. 25,p. 350 - 353.
Khimiya Prirodnykh Soedinenii,1989,p. 404 - 408.

4
[ 120550-35-8 ]
[ 60-32-2 ]
D-biotinyl-ε-aminocaproic acid [ No CAS ]

References: [1]Chemistry of Natural Compounds,1989,vol. 25,p. 350 - 353.
Khimiya Prirodnykh Soedinenii,1989,p. 404 - 408.

5
[ 120550-35-8 ]
[ 167700-41-6 ]
biotinyl-3-amino-O¹-dimethoxytrityl-1,2-propanediol [ No CAS ]

References: [1]Russian Journal of Bioorganic Chemistry,1994,vol. 20,p. 520 - 528.
Bioorganicheskaya Khimiya,1994,vol. 20,p. 955 - 966.

6
[ 771-61-9 ]
[ 58-85-5 ]
[ 120550-35-8 ]

Yield	Reaction Conditions	Operation in experiment
90%	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 0 - 20℃;Inert atmosphere;	Biotin (2.95 g, 12.00 mmol) was dissolved in DMF (10 mL), and Pfp-OH (2.80 g, 15.20 mmol) was added to the biotin solution before EDC.HCl (5.70 g, 29.70 mmol) in DMF (15 mL) were added to the mixture at 0 C over 30 min. The mixture stirred overnight at room temperature under nitrogen atmosphere. The product washed with DCM. White powder was obtained with a yield of 90% (4.50 g). The product was used in the next step without further purification. 1H NMR (D2O): d 1.41-1.69 (m, 6H, CH2), 2.57 (d, 1H,CH2), 2.77-2.85 (m, 3H, CH2), 3.11-3.12 (m, 1H, CH), 4.14 (t, 1H, CH), 4.30 (t, 1H, CH), 6.37 (d, 2H, NH).
	With dicyclohexyl-carbodiimide; In N,N-dimethyl-formamide; at 20℃;	EXAMPLE lO[D-(+)-biotinyl]-L-aspartate alpha-benzyl ester (14)To a suspension of D-Biotin (2.0 g, 8.19 mmol) in DMF (52 mL) was added pentafluorophenol (1.6 g, 15.6 mmol) followed by DCC (2.5 g, 12.3 mmol). The reaction mixture was allowed to stir, under nitrogen atmosphere, overnight at RT. The reaction mixture remained a suspension and was filtered off and concentrated. The residue was taken up into Et2theta and stirred for several minutes after which the suspension was filtered an dried und vacuum to give a white solid (2.58 g) ESI-MS: 411 [M+H]+. The solid was dissolved in DMF (90 mL) and Et3N (1.24 mL, 8.82 mmol, 1.4 equiv.) was added. H-Asp-OBn was added in portions as a solid. After approximately 15 min the reaction mixture became clear and an additional 2h stirring was allowed. The reaction mixture was concentrated under reduced pressure and water was added followed by MeOH (3:1). The solid formed was filtered off, washed with Et2theta and dried under vacuum to give compound 14 as a white solid (2.92 g, 77 %) ESI-MS: 450 [M+H]+.

References: [1]Synthetic Communications,1996,vol. 26,p. 2531 - 2547.
[2]Journal of the American Chemical Society,2009,vol. 131,p. 7954 - 7955.
[3]Russian Journal of Bioorganic Chemistry,1994,vol. 20,p. 520 - 528.
Bioorganicheskaya Khimiya,1994,vol. 20,p. 955 - 966.
[4]Organic and biomolecular chemistry,2003,vol. 1,p. 950 - 959.
[5]Chinese Chemical Letters,2017,vol. 28,p. 832 - 838.
[6]Biomacromolecules,2012,vol. 13,p. 2831 - 2842.
[7]Organic Letters,2008,vol. 10,p. 4453 - 4455.
[8]Russian Journal of Bioorganic Chemistry,2017,vol. 43,p. 386 - 396.
Bioorg. Khim.,2017,vol. 43,p. 377 - 387,11.
[9]Patent: WO2007/42469,2007,A2 .Location in patent: Page/Page column 20.

7
[ 120550-35-8 ]
[ 148704-81-8 ]
[ 148704-82-9 ]

References: [1]Synthetic Communications,1996,vol. 26,p. 2531 - 2547.

8
[ 120550-35-8 ]
[ 1926-80-3 ]
methyl 6-(+)-biotinylamidohexanoate [ No CAS ]

References: [1]Journal of labelled compounds and radiopharmaceuticals,2000,vol. 43,p. 309 - 322.

9
[ 120550-35-8 ]
2-{2-[6-amino-2-(2-tert-butoxycarbonylamino-5-guanidino-pentanoylamino)-hexanoylamino]-3-tert-butoxycarbonyl-propionylamino}-3-methyl-butyric acid tert-butyl ester [ No CAS ]
Boc-Arg(HCl)-Lys[(+)-biotinyl]-Asp(Ot-Bu)-Val-Ot-Bu [ No CAS ]

References: [1]Journal of labelled compounds and radiopharmaceuticals,2000,vol. 43,p. 309 - 322.

10
[ 120550-35-8 ]
H-Arg(HCl)-Lys(Boc)-Asp(Ot-Bu)-Val-Ot-Bu*HCl [ No CAS ]
[(+)-biotinyl]-Arg(HCl)-Lys(Boc)-Asp(Ot-Bu)-Val-Ot-Bu [ No CAS ]

References: [1]Journal of labelled compounds and radiopharmaceuticals,2000,vol. 43,p. 309 - 322.

11
[ 120550-35-8 ]
[ 101187-40-0 ]
[ 418759-44-1 ]

References: [1]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 625 - 637.

12
[ 929-59-9 ]
[ 120550-35-8 ]
[ 138529-46-1 ]

References: [1]Organic and biomolecular chemistry,2003,vol. 1,p. 950 - 959.
[2]Biomacromolecules,2012,vol. 13,p. 2831 - 2842.

13
[ 120550-35-8 ]
(3aR,8bS)-7-Amino-3-[1-((R)-4-methyl-5-oxo-2,5-dihydro-furan-2-yloxy)-meth-(E)-ylidene]-3,3a,4,8b-tetrahydro-indeno[1,2-b]furan-2-one [ No CAS ]
N₁-[(3aRS,8bSR)-3-((E)-1-[(2RS)-4-methyl-5-oxo-2,5-dihydro-2-furanyl]oxymethylidene)-2-oxo-3,3a,4,8b-tetrahydro-2H-indeno[1,2-b]furan-7-yl]-5-(2-oxoperhydrothieno[3,4-d]imidazol-4-yl)pentanamide [ No CAS ]

References: [1]Organic and biomolecular chemistry,2003,vol. 1,p. 950 - 959.

14
[ 120550-35-8 ]
[ 486445-72-1 ]
5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid (3-{2-[2-(3-{(R)-4-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-2-hydroxy-butyrylamino}-propoxy)-ethoxy]-ethoxy}-propyl)-amide [ No CAS ]

References: [1]Organic Letters,2002,vol. 4,p. 4607 - 4610.

15
[ 120550-35-8 ]
N-(3-amino-propyl)-N-[4-(4-azidomethyl-benzoyl)-benzyl]-4-nitro-benzenesulfonamide [ No CAS ]
5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid {3-[[4-(4-azidomethyl-benzoyl)-benzyl]-(4-nitro-benzenesulfonyl)-amino]-propyl}-amide [ No CAS ]

References: [1]Chemical Communications,2003,p. 2244 - 2245.

16
[ 120550-35-8 ]
N-(3-amino-propyl)-N-{4-[4-(tert-butyl-dimethyl-silanyloxymethyl)-benzoyl]-benzyl}-4-nitro-benzenesulfonamide [ No CAS ]
5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid {3-[{4-[4-(tert-butyl-dimethyl-silanyloxymethyl)-benzoyl]-benzyl}-(4-nitro-benzenesulfonyl)-amino]-propyl}-amide [ No CAS ]

References: [1]Chemical Communications,2003,p. 2244 - 2245.

17
[ 120550-35-8 ]
N-(8-amino-octyl)-N-[4-(4-azidomethyl-benzoyl)-benzyl]-4-nitro-benzenesulfonamide [ No CAS ]
5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid {8-[[4-(4-azidomethyl-benzoyl)-benzyl]-(4-nitro-benzenesulfonyl)-amino]-octyl}-amide [ No CAS ]

References: [1]Chemical Communications,2003,p. 2244 - 2245.

18
[ 77837-46-8 ]
[ 120550-35-8 ]
N,N-dimethyl-N'-(4-biotinamidophenylsulfonyl)-ethylenediamine [ No CAS ]

References: [1]Journal of the American Chemical Society,2006,vol. 128,p. 8320 - 8328.

19
C₃₇H₃₈N₂OP₂ [ No CAS ]
[ 120550-35-8 ]
N-((R)-1-(bis(2-(diphenylphosphino)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-((3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide [ No CAS ]

References: [1]Chemical Communications,2005,p. 4815 - 4817.

20
C₃₇H₃₈N₂OP₂ [ No CAS ]
[ 120550-35-8 ]
N-((S)-1-(bis(2-(diphenylphosphino)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-((3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide [ No CAS ]

References: [1]Chemical Communications,2005,p. 4815 - 4817.

21
C₃₃H₃₆N₂OP₂ [ No CAS ]
[ 120550-35-8 ]
(R)-N,N-bis(2-(diphenylphosphino)ethyl)-1-(5-((3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl)pyrrolidine-2-carboxamide [ No CAS ]

References: [1]Chemical Communications,2005,p. 4815 - 4817.

22
C₃₃H₃₆N₂OP₂ [ No CAS ]
[ 120550-35-8 ]
(S)-N,N-bis(2-(diphenylphosphino)ethyl)-1-(5-((3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl)pyrrolidine-2-carboxamide [ No CAS ]

References: [1]Chemical Communications,2005,p. 4815 - 4817.

23
C₃₁H₄₃F₃N₈O₅S [ No CAS ]
[ 120550-35-8 ]
[ 943601-18-1 ]